COVID-19大流行对美国专科治疗的严重哮喘患者哮喘发作和住院率的影响:来自CHRONICLE研究的结果

W. Moore, D. Ledford, D. Carstens, C. Ambrose
{"title":"COVID-19大流行对美国专科治疗的严重哮喘患者哮喘发作和住院率的影响:来自CHRONICLE研究的结果","authors":"W. Moore, D. Ledford, D. Carstens, C. Ambrose","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1289","DOIUrl":null,"url":null,"abstract":"RATIONALE: The impact of the COVID-19 pandemic on disease control in patients with severe asthma (SA) has not been described. Anecdotal reports suggest that social distancing, exposure avoidance, and restrictions on travel may have impacted the incidence of asthma exacerbations. Methods: CHRONICLE is an observational study of specialist-treated US adults (aged ≥18 years) with SA. At enrollment, patients must be: (1) receiving FDAapproved monoclonal antibody therapy for SA;(2) receiving systemic corticosteroids (SCS) or other systemic immunosuppressants for ≥50% of the prior 12 months;or (3) persistently uncontrolled while treated with highdosage inhaled corticosteroids and additional controllers. Specialists report all exacerbations and asthma hospitalizations for enrolled patients from 12 months prior to enrollment, with updates provided every 6 months. To describe the effect of the COVID-19 pandemic, we calculated the incidence of these events by month from July 2018 to May 2020 (latest month with complete data) among patients enrolled through November 2020. Results: Among enrolled patients (N=2633), specialist-reported exacerbations and asthma hospitalizations declined significantly in April and May 2020, following varying state/local COVID-19-related stay-at-home orders and social distancing recommendations. Relative to the average rates from July 2018 to March 2020, exacerbations (Figure panel A) and asthma hospitalizations (Figure panel B) were 47% and 57% lower, respectively, in April 2020 and 72% and 74% lower, respectively, in May 2020. Relative to the same months in 2019, exacerbations and asthma hospitalizations were 49% and 58% lower, respectively, in April 2020 and 67% and 74% lower, respectively, in May 2020. Conclusions: There was a notable decline in exacerbations and asthma hospitalizations among US patients with SA coincident with COVID-19-related stay-at-home orders and social distancing recommendations. Reasons for these declines are likely multifactorial and may be explained by reduced viral infections due to reduced social contact, altered patient behavior, and possibly reduced access to care. Rates in later months will be evaluated as data become available.","PeriodicalId":320542,"journal":{"name":"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS","volume":"192 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Impact of COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Specialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study\",\"authors\":\"W. Moore, D. Ledford, D. Carstens, C. Ambrose\",\"doi\":\"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"RATIONALE: The impact of the COVID-19 pandemic on disease control in patients with severe asthma (SA) has not been described. Anecdotal reports suggest that social distancing, exposure avoidance, and restrictions on travel may have impacted the incidence of asthma exacerbations. Methods: CHRONICLE is an observational study of specialist-treated US adults (aged ≥18 years) with SA. At enrollment, patients must be: (1) receiving FDAapproved monoclonal antibody therapy for SA;(2) receiving systemic corticosteroids (SCS) or other systemic immunosuppressants for ≥50% of the prior 12 months;or (3) persistently uncontrolled while treated with highdosage inhaled corticosteroids and additional controllers. Specialists report all exacerbations and asthma hospitalizations for enrolled patients from 12 months prior to enrollment, with updates provided every 6 months. To describe the effect of the COVID-19 pandemic, we calculated the incidence of these events by month from July 2018 to May 2020 (latest month with complete data) among patients enrolled through November 2020. Results: Among enrolled patients (N=2633), specialist-reported exacerbations and asthma hospitalizations declined significantly in April and May 2020, following varying state/local COVID-19-related stay-at-home orders and social distancing recommendations. Relative to the average rates from July 2018 to March 2020, exacerbations (Figure panel A) and asthma hospitalizations (Figure panel B) were 47% and 57% lower, respectively, in April 2020 and 72% and 74% lower, respectively, in May 2020. Relative to the same months in 2019, exacerbations and asthma hospitalizations were 49% and 58% lower, respectively, in April 2020 and 67% and 74% lower, respectively, in May 2020. Conclusions: There was a notable decline in exacerbations and asthma hospitalizations among US patients with SA coincident with COVID-19-related stay-at-home orders and social distancing recommendations. Reasons for these declines are likely multifactorial and may be explained by reduced viral infections due to reduced social contact, altered patient behavior, and possibly reduced access to care. Rates in later months will be evaluated as data become available.\",\"PeriodicalId\":320542,\"journal\":{\"name\":\"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS\",\"volume\":\"192 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1289\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

理由:尚未描述COVID-19大流行对严重哮喘(SA)患者疾病控制的影响。坊间报告显示,保持社交距离、避免接触和限制旅行可能会影响哮喘加重的发病率。方法:CHRONICLE是一项观察性研究,研究对象是接受专科治疗的美国SA成人(年龄≥18岁)。在入组时,患者必须:(1)接受fda批准的SA单克隆抗体治疗;(2)在过去12个月内接受系统性皮质类固醇(SCS)或其他系统性免疫抑制剂≥50%;或(3)在接受大剂量吸入皮质类固醇和其他控制器治疗时持续不受控制。专家报告入组患者在入组前12个月的所有急性发作和哮喘住院情况,每6个月更新一次。为了描述COVID-19大流行的影响,我们在截至2020年11月的入组患者中按月计算了2018年7月至2020年5月(数据完整的最后一个月)这些事件的发生率。结果:在纳入的患者(N=2633)中,在不同的州/地方与covid -19相关的居家令和社交距离建议之后,专家报告的急性发作和哮喘住院率在2020年4月和5月显著下降。与2018年7月至2020年3月的平均发病率相比,2020年4月的急性发作(图A)和哮喘住院(图B)分别降低了47%和57%,2020年5月分别降低了72%和74%。与2019年同期相比,2020年4月的急性发作和哮喘住院率分别降低了49%和58%,2020年5月的急性发作和哮喘住院率分别降低了67%和74%。结论:根据与covid -19相关的居家令和社交距离建议,美国SA患者的病情恶化和哮喘住院率显著下降。这些下降的原因可能是多因素的,可能是由于社会接触减少、患者行为改变以及可能获得护理的机会减少而导致病毒感染减少。以后几个月的费率将在获得数据后加以评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Specialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study
RATIONALE: The impact of the COVID-19 pandemic on disease control in patients with severe asthma (SA) has not been described. Anecdotal reports suggest that social distancing, exposure avoidance, and restrictions on travel may have impacted the incidence of asthma exacerbations. Methods: CHRONICLE is an observational study of specialist-treated US adults (aged ≥18 years) with SA. At enrollment, patients must be: (1) receiving FDAapproved monoclonal antibody therapy for SA;(2) receiving systemic corticosteroids (SCS) or other systemic immunosuppressants for ≥50% of the prior 12 months;or (3) persistently uncontrolled while treated with highdosage inhaled corticosteroids and additional controllers. Specialists report all exacerbations and asthma hospitalizations for enrolled patients from 12 months prior to enrollment, with updates provided every 6 months. To describe the effect of the COVID-19 pandemic, we calculated the incidence of these events by month from July 2018 to May 2020 (latest month with complete data) among patients enrolled through November 2020. Results: Among enrolled patients (N=2633), specialist-reported exacerbations and asthma hospitalizations declined significantly in April and May 2020, following varying state/local COVID-19-related stay-at-home orders and social distancing recommendations. Relative to the average rates from July 2018 to March 2020, exacerbations (Figure panel A) and asthma hospitalizations (Figure panel B) were 47% and 57% lower, respectively, in April 2020 and 72% and 74% lower, respectively, in May 2020. Relative to the same months in 2019, exacerbations and asthma hospitalizations were 49% and 58% lower, respectively, in April 2020 and 67% and 74% lower, respectively, in May 2020. Conclusions: There was a notable decline in exacerbations and asthma hospitalizations among US patients with SA coincident with COVID-19-related stay-at-home orders and social distancing recommendations. Reasons for these declines are likely multifactorial and may be explained by reduced viral infections due to reduced social contact, altered patient behavior, and possibly reduced access to care. Rates in later months will be evaluated as data become available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信